868601-06-3Relevant academic research and scientific papers
Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs
-
Page/Page column 7, (2008/12/04)
Compounds of the formula which are selective beta-3-agonists and useful for the treatment of obesity and type II diabetes. Exemplary compounds are: ethyl 3-{3-[(R)-2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-3H-imidazo[4,5-b]p
Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments
-
Page/Page column 9, (2009/01/20)
Compounds of general formula (I) which are selective beta-3-agonists and useful for the treatment of obesity and type II diabetes. Exemplary compounds are: [4-(1-{3-[2-(3-phenylsulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazol-4-yl)
Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions
-
Page/Page column 10, (2010/11/27)
The present invention relates to new beta-agonists of general formula (I) wherein the groups R1 and R2 have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers, solvates, hydrates,
Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions
-
Page/Page column 11-12, (2010/11/27)
The present invention relates to new beta-agonists of general formula (I) wherein the groups R1 to R4 have the meanings given in ths claims and specification, the tautomers, racemates, enantiomers, diastereomers, solvates, hydrates,
NOVEL BETA AGONISTS, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS
-
Page/Page column 35, (2010/02/14)
The invention relates to the novel beta agonists of general formula (I); wherein the groups R1 to R7 are defined as in the claims and the description, and to the tautomers, enantiomers, diastereomers, mixtures, prodrugs and salts the
Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions
-
Page/Page column 14, (2010/02/14)
The present invention relates to new beta-agonists of general formula (I) wherein the groups R1 to R7 have the meanings given in the claims and specification, the tautomers, the enantiomers, the diastereomers, the mixtures thereof, t
